background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

KIF18A

Kinase-like protein 18A (KIF18A) is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers.1-3

Preclinical studies of KIF18A gene inactivation suggest its function can be dispensable for normal somatic cell division,4,5 but cancer cells with chromosomal instability depend on KIF18A for cell division and survival,6,7 making KIF18A a potential therapeutic target.

References
1. Rath O, et al. Nat Rev Cancer. 2012;12:527-539. 2. Mayr MI, et al. Curr Biol. 2007;17:488-498. 3. Stumpff J, et al. Dev Cell. 2008;14:252-262. 4. Czechanski A, et al. Dev Biol. 2015;402:253-262. 5. Fonseca CL, et al. J Cell Biol. 2019;218:1148-1163. 6. Marquis C, et al. Nat Comm. 2021;12:1213. 7. Quinton RJ, et al. Nature. 2021;590:492-497. 8. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 7/27/21. 9. Govindan R, et al. Presented at: American Society of Clinical Oncology; Virtual Meeting; June 4–8, 2021.
Molecule
Modality8
Target9
Areas of Investigation8
AMG 650
Target9
KIF18A
Areas of Investigation8
References
1. Rath O, et al. Nat Rev Cancer. 2012;12:527-539. 2. Mayr MI, et al. Curr Biol. 2007;17:488-498. 3. Stumpff J, et al. Dev Cell. 2008;14:252-262. 4. Czechanski A, et al. Dev Biol. 2015;402:253-262. 5. Fonseca CL, et al. J Cell Biol. 2019;218:1148-1163. 6. Marquis C, et al. Nat Comm. 2021;12:1213. 7. Quinton RJ, et al. Nature. 2021;590:492-497. 8. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 7/27/21. 9. Govindan R, et al. Presented at: American Society of Clinical Oncology; Virtual Meeting; June 4–8, 2021.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.